Industries > Pharma > The Global Respiratory Inhalers Market 2018-2028

The Global Respiratory Inhalers Market 2018-2028

Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others

PUBLISHED: 24 October 2018
PAGES: 165
PRODUCT CODE: PHA0337
SUBMARKET: Medical Devices

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0337 Categories: , Tags: , , , ,

The global respiratory inhalers market reached $33bn in 2017 and is estimated to reach $38bn by 2023. In 2017, the asthma segment held 58% of the global respiratory inhalers market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 165-page report you will receive 121 charts– all unavailable elsewhere.

The 165-page report provides clear detailed insight into the respiratory inhalers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Respiratory Inhalers Market from 2018-2028

• Forecast of the Global Respiratory Inhalers market by Type of Product:
• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs): Single-dose DPIs, Multi-dose DPIs
• Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers

• Forecast of the Global Respiratory Inhalers market by Indication:
• Asthma
• COPD
• Other Respiratory Diseases

The Global Respiratory Inhalers Market 2018-2028

• This report provides individual revenue forecasts to 2028 for these national markets:
• The US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• India
• Russia
• Brazil
• Mexico
• Canada

• Our study discusses the selected leading companies that are the major players in the respiratory inhalers market:
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Teva

• This report discusses factors that drive and restrain this market. As well as opportunities and challenges faced by this market.

• This report discusses the Porter’s Five Forces Analysis of the respiratory inhalers market.

Visiongain’s study is intended for anyone requiring commercial analyses for the respiratory inhalers market. You find data, trends and predictions.

Buy our report today The Global Respiratory Inhalers Market Analysis : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for The Global Respiratory Inhalers Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for The Global Respiratory Inhalers Market 2018-2028


Latest Pharma news

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

READ